216 related articles for article (PubMed ID: 34036233)
1. Long-Term Outcomes in a Multicenter, Prospective Cohort Evaluating the Prognostic 31-Gene Expression Profile for Cutaneous Melanoma.
Hsueh EC; DeBloom JR; Lee JH; Sussman JJ; Covington KR; Caruso HG; Quick AP; Cook RW; Slingluff CL; McMasters KM
JCO Precis Oncol; 2021; 5():. PubMed ID: 34036233
[TBL] [Abstract][Full Text] [Related]
2. Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test.
Hsueh EC; DeBloom JR; Lee J; Sussman JJ; Covington KR; Middlebrook B; Johnson C; Cook RW; Slingluff CL; McMasters KM
J Hematol Oncol; 2017 Aug; 10(1):152. PubMed ID: 28851416
[TBL] [Abstract][Full Text] [Related]
3. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients.
Zager JS; Gastman BR; Leachman S; Gonzalez RC; Fleming MD; Ferris LK; Ho J; Miller AR; Cook RW; Covington KR; Meldi-Plasseraud K; Middlebrook B; Kaminester LH; Greisinger A; Estrada SI; Pariser DM; Cranmer LD; Messina JL; Vetto JT; Wayne JD; Delman KA; Lawson DH; Gerami P
BMC Cancer; 2018 Feb; 18(1):130. PubMed ID: 29402264
[TBL] [Abstract][Full Text] [Related]
4. Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma.
Keller J; Schwartz TL; Lizalek JM; Chang ES; Patel AD; Hurley MY; Hsueh EC
Cancer Med; 2019 May; 8(5):2205-2212. PubMed ID: 30950242
[TBL] [Abstract][Full Text] [Related]
5. Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile-based classification.
Ferris LK; Farberg AS; Middlebrook B; Johnson CE; Lassen N; Oelschlager KM; Maetzold DJ; Cook RW; Rigel DS; Gerami P
J Am Acad Dermatol; 2017 May; 76(5):818-825.e3. PubMed ID: 28110997
[TBL] [Abstract][Full Text] [Related]
6. Expanded evidence that the 31-gene expression profile test provides clinical utility for melanoma management in a multicenter study.
Dillon LD; McPhee M; Davidson RS; Quick AP; Martin B; Covington KR; Zolochevska O; Cook RW; Vetto JT; Jarell AD; Fleming MD
Curr Med Res Opin; 2022 Aug; 38(8):1267-1274. PubMed ID: 35081854
[TBL] [Abstract][Full Text] [Related]
7. Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria.
Gastman BR; Gerami P; Kurley SJ; Cook RW; Leachman S; Vetto JT
J Am Acad Dermatol; 2019 Jan; 80(1):149-157.e4. PubMed ID: 30081113
[TBL] [Abstract][Full Text] [Related]
8. Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model.
Eggermont AMM; Bellomo D; Arias-Mejias SM; Quattrocchi E; Sominidi-Damodaran S; Bridges AG; Lehman JS; Hieken TJ; Jakub JW; Murphree DH; Pittelkow MR; Sluzevich JC; Cappel MA; Bagaria SP; Perniciaro C; Tjien-Fooh FJ; Rentroia-Pacheco B; Wever R; van Vliet MH; Dwarkasing J; Meves A
Eur J Cancer; 2020 Nov; 140():11-18. PubMed ID: 33032086
[TBL] [Abstract][Full Text] [Related]
9. The 31-gene expression profile stratifies recurrence and metastasis risk in patients with cutaneous melanoma.
Jarell A; Skenderis B; Dillon LD; Dillon K; Martin B; Quick AP; Siegel JJ; Rackley BB; Cook RW
Future Oncol; 2021 Dec; 17(36):5023-5031. PubMed ID: 34587770
[TBL] [Abstract][Full Text] [Related]
10. Utility of a 31-gene expression profile for predicting outcomes in patients with primary cutaneous melanoma referred for sentinel node biopsy.
Arnot SP; Han G; Fortino J; Han D; Fowler G; Vetto JT
Am J Surg; 2021 Jun; 221(6):1195-1199. PubMed ID: 33773750
[TBL] [Abstract][Full Text] [Related]
11. CORRELATION OF GENE EXPRESSION PROFILE STATUS AND AMERICAN JOINT COMMISSION ON CANCER STAGE IN UVEAL MELANOMA.
Berry DE; Schefler AC; Seider MI; Materin M; Stinnett S; Mruthyunjaya P;
Retina; 2020 Feb; 40(2):214-224. PubMed ID: 31972790
[TBL] [Abstract][Full Text] [Related]
12. Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma.
Amaral TMS; Hoffmann MC; Sinnberg T; Niessner H; Sülberg H; Eigentler TK; Garbe C
Eur J Cancer; 2020 Jan; 125():38-45. PubMed ID: 31838403
[TBL] [Abstract][Full Text] [Related]
13. Improved cutaneous melanoma survival stratification through integration of 31-gene expression profile testing with the American Joint Committee on Cancer 8th Edition Staging.
Wisco OJ; Marson JW; Litchman GH; Brownstone N; Covington KR; Martin BJ; Quick AP; Siegel JJ; Caruso HG; Cook RW; Winkelmann RR; Rigel DS
Melanoma Res; 2022 Apr; 32(2):98-102. PubMed ID: 35254332
[TBL] [Abstract][Full Text] [Related]
14. Molecular risk prediction in cutaneous melanoma: A meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients.
Greenhaw BN; Covington KR; Kurley SJ; Yeniay Y; Cao NA; Plasseraud KM; Cook RW; Hsueh EC; Gastman BR; Wei ML
J Am Acad Dermatol; 2020 Sep; 83(3):745-753. PubMed ID: 32229276
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit.
Grossman D; Okwundu N; Bartlett EK; Marchetti MA; Othus M; Coit DG; Hartman RI; Leachman SA; Berry EG; Korde L; Lee SJ; Bar-Eli M; Berwick M; Bowles T; Buchbinder EI; Burton EM; Chu EY; Curiel-Lewandrowski C; Curtis JA; Daud A; Deacon DC; Ferris LK; Gershenwald JE; Grossmann KF; Hu-Lieskovan S; Hyngstrom J; Jeter JM; Judson-Torres RL; Kendra KL; Kim CC; Kirkwood JM; Lawson DH; Leming PD; Long GV; Marghoob AA; Mehnert JM; Ming ME; Nelson KC; Polsky D; Scolyer RA; Smith EA; Sondak VK; Stark MS; Stein JA; Thompson JA; Thompson JF; Venna SS; Wei ML; Swetter SM
JAMA Dermatol; 2020 Sep; 156(9):1004-1011. PubMed ID: 32725204
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of a Gene Expression Profiling Assay in Primary Cutaneous Melanoma.
Kangas-Dick AW; Greenbaum A; Gall V; Groisberg R; Mehnert J; Chen C; Moore DF; Berger AC; Koshenkov V
Ann Surg Oncol; 2021 Aug; 28(8):4582-4589. PubMed ID: 33486642
[TBL] [Abstract][Full Text] [Related]
17. Gene Expression Profiling Prognostication of Posterior Uveal Melanoma: Does Size Matter?
Binkley EM; Bena JF; Davanzo JM; Hinz C; Boldt HC; Singh AD
Ophthalmol Retina; 2020 Jun; 4(6):620-629. PubMed ID: 32081600
[TBL] [Abstract][Full Text] [Related]
18. The 31-Gene Expression Profile Test Outperforms AJCC in Stratifying Risk of Recurrence in Patients with Stage I Cutaneous Melanoma.
Podlipnik S; Martin BJ; Morgan-Linnell SK; Bailey CN; Siegel JJ; Petkov VI; Puig S
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254778
[TBL] [Abstract][Full Text] [Related]
19. Identification of stage I/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP).
Amaral T; Sinnberg T; Chatziioannou E; Niessner H; Leiter U; Keim U; Forschner A; Dwarkasing J; Tjien-Fooh F; Wever R; Flatz L; Eggermont A; Forchhammer S
Eur J Cancer; 2023 Mar; 182():155-162. PubMed ID: 36739215
[TBL] [Abstract][Full Text] [Related]
20. Impact of Gene Expression Profiling on Decision-Making in Clinically Node Negative Melanoma Patients after Surgical Staging.
Schuitevoerder D; Heath M; Cook RW; Covington KR; Fortino J; Leachman S; Vetto JT
J Drugs Dermatol; 2018 Feb; 17(2):196-199. PubMed ID: 29462228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]